Bone marrow transplant nephropathy successfully treated with angiotensin-converting enzyme inhibitor

Shizunori Ichida, Keiko Okada, Michie Itoh, Rieko Okada, Noritoshi Katoh, Masanobu Kasai, Yukio Yuzawa

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We report a patient who developed chronic renal failure 11 months after an allogeneic hematopoietic stem-cell transplantation (HSCT) for Ph1+ acute lymphocytic leukemia. Renal biopsy showed typical pathological findings compatible with a bone marrow transplant nephropathy (BMT nephropathy). The general course of BMT nephropathy is slowly progressive, eventually reaching endstage renal failure. Intervention therapy with an angiotensin-converting enzyme inhibitor (ACE-I), temocapril, was started for this patient, based on several experimental reports showing the protective effects of ACE-Is on BMT nephropathy. After the induction of ACE-I in this patient, the rate of regression of renal function was significantly reduced and his serum creatinine was maintained at almost the same level for 18 months. Although the course of observation in this patient was short, we clearly showed the effects of an ACE-I on preventing BMT nephropathy from progressing to endstage renal failure in a human rather than in an experimental model.

Original languageEnglish
Pages (from-to)78-81
Number of pages4
JournalClinical and Experimental Nephrology
Volume10
Issue number1
DOIs
Publication statusPublished - 01-03-2006
Externally publishedYes

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
Bone Marrow
Transplants
Renal Insufficiency
Kidney
Hematopoietic Stem Cell Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Chronic Kidney Failure
Creatinine
Theoretical Models
Observation
Biopsy
Serum
Therapeutics

All Science Journal Classification (ASJC) codes

  • Physiology
  • Nephrology
  • Physiology (medical)

Cite this

Ichida, Shizunori ; Okada, Keiko ; Itoh, Michie ; Okada, Rieko ; Katoh, Noritoshi ; Kasai, Masanobu ; Yuzawa, Yukio. / Bone marrow transplant nephropathy successfully treated with angiotensin-converting enzyme inhibitor. In: Clinical and Experimental Nephrology. 2006 ; Vol. 10, No. 1. pp. 78-81.
@article{2441bb6ad210430eac4201363df2f1e2,
title = "Bone marrow transplant nephropathy successfully treated with angiotensin-converting enzyme inhibitor",
abstract = "We report a patient who developed chronic renal failure 11 months after an allogeneic hematopoietic stem-cell transplantation (HSCT) for Ph1+ acute lymphocytic leukemia. Renal biopsy showed typical pathological findings compatible with a bone marrow transplant nephropathy (BMT nephropathy). The general course of BMT nephropathy is slowly progressive, eventually reaching endstage renal failure. Intervention therapy with an angiotensin-converting enzyme inhibitor (ACE-I), temocapril, was started for this patient, based on several experimental reports showing the protective effects of ACE-Is on BMT nephropathy. After the induction of ACE-I in this patient, the rate of regression of renal function was significantly reduced and his serum creatinine was maintained at almost the same level for 18 months. Although the course of observation in this patient was short, we clearly showed the effects of an ACE-I on preventing BMT nephropathy from progressing to endstage renal failure in a human rather than in an experimental model.",
author = "Shizunori Ichida and Keiko Okada and Michie Itoh and Rieko Okada and Noritoshi Katoh and Masanobu Kasai and Yukio Yuzawa",
year = "2006",
month = "3",
day = "1",
doi = "10.1007/s10157-005-0394-3",
language = "English",
volume = "10",
pages = "78--81",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",
number = "1",

}

Bone marrow transplant nephropathy successfully treated with angiotensin-converting enzyme inhibitor. / Ichida, Shizunori; Okada, Keiko; Itoh, Michie; Okada, Rieko; Katoh, Noritoshi; Kasai, Masanobu; Yuzawa, Yukio.

In: Clinical and Experimental Nephrology, Vol. 10, No. 1, 01.03.2006, p. 78-81.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bone marrow transplant nephropathy successfully treated with angiotensin-converting enzyme inhibitor

AU - Ichida, Shizunori

AU - Okada, Keiko

AU - Itoh, Michie

AU - Okada, Rieko

AU - Katoh, Noritoshi

AU - Kasai, Masanobu

AU - Yuzawa, Yukio

PY - 2006/3/1

Y1 - 2006/3/1

N2 - We report a patient who developed chronic renal failure 11 months after an allogeneic hematopoietic stem-cell transplantation (HSCT) for Ph1+ acute lymphocytic leukemia. Renal biopsy showed typical pathological findings compatible with a bone marrow transplant nephropathy (BMT nephropathy). The general course of BMT nephropathy is slowly progressive, eventually reaching endstage renal failure. Intervention therapy with an angiotensin-converting enzyme inhibitor (ACE-I), temocapril, was started for this patient, based on several experimental reports showing the protective effects of ACE-Is on BMT nephropathy. After the induction of ACE-I in this patient, the rate of regression of renal function was significantly reduced and his serum creatinine was maintained at almost the same level for 18 months. Although the course of observation in this patient was short, we clearly showed the effects of an ACE-I on preventing BMT nephropathy from progressing to endstage renal failure in a human rather than in an experimental model.

AB - We report a patient who developed chronic renal failure 11 months after an allogeneic hematopoietic stem-cell transplantation (HSCT) for Ph1+ acute lymphocytic leukemia. Renal biopsy showed typical pathological findings compatible with a bone marrow transplant nephropathy (BMT nephropathy). The general course of BMT nephropathy is slowly progressive, eventually reaching endstage renal failure. Intervention therapy with an angiotensin-converting enzyme inhibitor (ACE-I), temocapril, was started for this patient, based on several experimental reports showing the protective effects of ACE-Is on BMT nephropathy. After the induction of ACE-I in this patient, the rate of regression of renal function was significantly reduced and his serum creatinine was maintained at almost the same level for 18 months. Although the course of observation in this patient was short, we clearly showed the effects of an ACE-I on preventing BMT nephropathy from progressing to endstage renal failure in a human rather than in an experimental model.

UR - http://www.scopus.com/inward/record.url?scp=33645055071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645055071&partnerID=8YFLogxK

U2 - 10.1007/s10157-005-0394-3

DO - 10.1007/s10157-005-0394-3

M3 - Article

C2 - 16544182

AN - SCOPUS:33645055071

VL - 10

SP - 78

EP - 81

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

IS - 1

ER -